MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$710M
(-52.38%↓ Y/Y)
Proceeds from issuance of
common stock through...
$23M
(64.29%↑ Y/Y)
Proceeds from sales of
marketable securities
$212M
(-42.86%↓ Y/Y)
Net cash provided by
investing activities
$329M
(-41.67%↓ Y/Y)
Net cash provided by
financing activities
$14M
(55.56%↑ Y/Y)
Canceled cashflow
$593M
Canceled cashflow
$9M
Net decrease in
cash, cash...
-$185M
(46.38%↑ Y/Y)
Canceled cashflow
$343M
Deferred revenue
$190M
(95.88%↑ Y/Y)
Stock-based compensation
$120M
(-7.69%↓ Y/Y)
Depreciation and
amortization
$63M
(10.53%↑ Y/Y)
Accounts receivable, net
-$53M
(-76.67%↓ Y/Y)
Prepaid expenses and
other assets
-$16M
(-108.16%↓ Y/Y)
Accrued liabilities
$11M
(178.57%↑ Y/Y)
Right-of-use assets,
operating leases
-$10M
(0.00%↑ Y/Y)
Other non-cash items
-$4M
(88.24%↑ Y/Y)
Purchases of marketable
securities
$556M
(-57.07%↓ Y/Y)
Purchases of property,
plant and equipment
$37M
(1133.33%↑ Y/Y)
Changes in financing
lease liabilities
$7M
(40.00%↑ Y/Y)
Tax payments
related to net share...
$2M
Net cash used in
operating activities
-$526M
(42.76%↑ Y/Y)
Canceled cashflow
$467M
Effect of changes in
exchange rates on cash and...
-$2M
Net loss
-$782M
(5.21%↑ Y/Y)
Inventory
$132M
(15.79%↑ Y/Y)
Other liabilities
-$53M
(8.62%↑ Y/Y)
Amortization/accretion of investments
$10M
(-44.44%↓ Y/Y)
Operating lease
liabilities
-$8M
(-60.00%↓ Y/Y)
Accounts payable
-$8M
(82.98%↑ Y/Y)
Back
Back
Cash Flow
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)
Master Final R&D Day 2021 Slides (09
source: myfinsight.com
Moderna, Inc. (MRNA)